Syngeneic natural killer cell therapy activates dendritic and T cells in metastatic lungs and effectively treats low-burden metastases
eLife · 2025
DOI: 10.7554/elife.99010 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2025. Verfasst von Shih-Wen Huang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan. Hauptthemen laut MEDLINE: Killer Cells, Natural, Lung Neoplasms, Dendritic Cells, Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology, Taiwan, Academia Sinica.
Abstract (Originalsprache)
Natural killer (NK) cells can control metastasis through cytotoxicity and IFN-γ production independently of T cells in experimental metastasis mouse models. The inverse correlation between NK activity and metastasis incidence supports a critical role for NK cells in human metastatic surveillance. However, autologous NK cell therapy has shown limited benefit in treating patients with metastatic solid tumors. Using a spontaneous metastasis mouse model of MHC-I + breast cancer, we found that transfer of IL-15/IL-12-conditioned syngeneic NK cells after primary tumor resection promoted long-term survival of mice with low metastatic burden and induced a tumor-specific protective T cell response that is essential for the therapeutic effect. Furthermore, NK cell transfer augments activation of conventional dendritic cells (cDCs), Foxp3 - CD4 + T cells and stem cell-like CD8 + T cells in metastatic lungs, to which IFN-γ of the transferred NK cells contributes significantly. These results imply direct interactions between transferred NK cells and endogenous cDCs to enhance T cell activation. We conducted an investigator-initiated clinical trial of autologous NK cell therapy in six patients with advanced cancer and observed that the NK cell therapy was safe and showed signs of effectiveness. These findings indicate that autologous NK cell therapy is effective in treating established low burden metastases of MHC-I + tumor cells by activating the cDC-T cell axis at metastatic sites.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan.
- Molecular and Cell Biology, Taiwan International Graduate Program, Academia Sinica and Graduate Institute of Life Science, National Defense Medical Center, Taipei, Taiwan.
- Department of Life Sciences, National Central University, Taoyuan, Taiwan.
- National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
- Institute of Statistical Science, Academia Sinica, Taipei, Taiwan.
- Department of Hematology-Oncology, Tri-Service General Hospital, Taipei, Taiwan.
ORCID-Profile: Yein-Gei Lai, Hao-Ting Liao, Nan-Shih Liao
Förderung
- Ministry of Science and Technology, Taiwan
- Academia Sinica
Zitieren
APA
Huang, S. W., Lai, Y. G., Liao, H. T., Chang, C. L., Ma, R. Y., Chen, Y. H., Liou, Y. H., Wu, Z. Q., Wu, Y. C., Liu, K. J., Huang, Y. T., Yang, J. L., Dai, M. S., & Liao, N. S. (2025). Syngeneic natural killer cell therapy activates dendritic and T cells in metastatic lungs and effectively treats low-burden metastases. eLife. https://doi.org/10.7554/elife.99010
Vancouver
Huang SW, Lai YG, Liao HT, Chang CL, Ma RY, Chen YH, et al. Syngeneic natural killer cell therapy activates dendritic and T cells in metastatic lungs and effectively treats low-burden metastases. eLife. 2025. doi:10.7554/elife.99010
BibTeX
@article{Huang2025,
author = {Huang, Shih-Wen and Lai, Yein-Gei and Liao, Hao-Ting and Chang, Chin-Ling and Ma, Ruo-Yu and Chen, Yung-Hsiang and Liou, Yae-Huei and Wu, Zhen-Qi and Wu, Yu-Chen and Liu, Ko-Jiunn and Huang, Yen-Tsung and Yang, Jen-Lung and Dai, Ming-Shen and Liao, Nan-Shih},
title = {Syngeneic natural killer cell therapy activates dendritic and T cells in metastatic lungs and effectively treats low-burden metastases},
journal = {eLife},
year = {2025},
doi = {10.7554/elife.99010}
}
EUVIMED